Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novartis ADR representing 1 Ord Shs NVS

Healthcare
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory... see more

Recent & Breaking News (NYSE:NVS)

Earnings Scheduled For October 25, 2016

Benzinga.com  October 25, 2016

Mid-Afternoon Market Update: Imperva Tumbles Amid Sale Concerns; Banc of California Shares Surge

Benzinga.com  October 19, 2016

Mid-Day Market Update: Crude Oil Up 2.75%; Cerulean Pharma Shares Surge On News Of Novartis Collaboration

Benzinga.com  October 19, 2016

Glaukos Way Ahead Of The Glaucoma Competition

Benzinga.com  September 23, 2016

Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions

PR Newswire September 23, 2016

Canada's Plan To Fight Opioid Addiction Might Hurt Its Weakest Patients

Benzinga.com  August 8, 2016

Regeneron Is 'One Of The Stronger Growers In Biotech'

Benzinga.com  June 29, 2016

Mid-Afternoon Market Update: Crude Oil Up 2.5%; Xencor Shares Surge Following Deal With Novartis

Benzinga.com  June 28, 2016

Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators

Benzinga.com  June 13, 2016

Bernstein Lists Active Buyers Of Ophthalmology Companies

Benzinga.com  June 9, 2016

4 Key Takeaways From ASCO

Benzinga.com  June 6, 2016

Switzerland ETF Sort Of Stable, But Currency Is An Issue

Benzinga.com  April 11, 2016

Story Behind the Charts - Featured Research on Johnson Controls, Novartis, Vulcan Materials, and NetEase

Accesswire February 10, 2016

Radius Health Announces Clinical Collaboration With a Leading Pharmaceutical Company to Evaluate RAD1901 Combination Regimens in Advanced Breast Cancer

GlobeNewswire January 27, 2016

A New ETF Avenue To Europe

Benzinga.com  December 31, 2015

Science 37 Secures $6.5M Series A Funding To Accelerate Clinical Trial Research

PR Newswire October 20, 2015

Novartis to sell drugs for heart disease, diabetes for $1 a month in poor countries

Canadian Press September 25, 2015

Hagens Berman: Class Action Alleges Novartis Gleevec Patent Infringement Suit a Sham

Business Wire June 24, 2015

Ovid Therapeutics Appoints Dr. Jeremy Levin as Chief Executive Officer

Business Wire April 16, 2015

Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery

Business Wire April 6, 2015